MAP2K7 and acute lymphoblastic leukemia: In addition, primary B-ALL blasts from relapsed patients exhibited increased cell death relative to matched diagnostic samples when treated with a MEK inhibitor, which in turn worked synergistically with glucocorticoid treatment in relapse samples [71].